Sophiris Bio Inc., of La Jolla, Calif., released top-line data from the 12-month follow-up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia in a Phase IIb study
Cempra Inc., of Chapel Hill, N.C., disclosed positive top-line data showing that solithromycin cleared infections in patients with uncomplicated urogenital gonorrhea
Active Biotech earned a milestone in May upon hitting the halfway mark in recruitment for the 1,200-patient study, and top-line data from the Phase III trial are expected by the end of 2013...Top-line data are expected later this quarter
Top-line data from Genzyme's second Phase III trial, ENCORE, also are expected in early 2013...Top-line data are anticipated in the second quarter of 2013
Clarus Therapeutics Inc., of Northbrook, Ill., said top-line data from the 90-day treatment phase of its ongoing Phase III study of CLR-610, an oral testosterone replacement product, demonstrated that 87 percent of the 141 men treated with CLR-610 achieved average serum T levels in the normal range (between 300 ng/dL and 1,000 ng/dL), the study's primary endpoint
ADX71149 also is being studied in a Phase II trial in positive and negative symptoms of schizophrenia, with top-line data expected in the fourth quarter
The company expects to report top-line data in early 2013...Separately, InSite Vision disclosed top-line data from a preclinical pharmacokinetic comparative study of DuraSite and DuraSite 2, its next-generation drug delivery system for ophthalmic therapeutics
Palatin Technologies Inc., of Cranbury, N.J., said the last patient completed treatment in its Phase IIb study testing melanocortin agonist bremelanotide in female sexual dysfunction, and top-line data are expected in the first half of next quarter
The company previously reported top-line data from the study, which missed its primary endpoint of reduced day 180 bronchiolitis obliterans syndrome in an intent-to-treat (ITTc) analysis, but achieved statistical significance in prospectively defined analyses of ITTc patients with their last observation carried forward and of ITTc patients treated per protocol...Top-line data for both studies is expected late in the second half of 2013
The companies reported top-line data from AFFIRM last year. (See BioWorld Today, Nov. 4, 2011...The double-blind, randomized study in 40 patients will produce top-line data by the middle of 2013
Pfizer Inc., of New York, reported top-line data showing that Lyrica (pregabalin) resulted in low discontinuation symptoms after tapering treatment following three months and six months in generalized anxiety disorder patients...In separate news, Pfizer reported top-line data showing that Lyrica does not affect the reproductive function in healthy males when compared to placebo
Anthera reported top-line data from the PEARL-SC study late last month, showing that the trial missed its primary endpoint, defined as clinical improvement at 24 weeks in the SLE responder index for the pooled blisibimod dose groups
Pergamum AB, of Stockholm, Sweden, a Karolinska Development AB portfolio company, reported top-line data from its Phase II trial of PXL-01 in subjects who have undergone tendon repair surgery
Biotie Therapies Oyj, of Turku, Finland, said it completed enrollment in its Phase IIb trial testing tozadenant in Parkinson's disease and expects top-line data to be available around the end of the year
Sophiris Bio Inc., of La Jolla, Calif., released top-line data from the 12-month follow-up of patients receiving PRX302 for the treatment of benign prostatic hyperplasia in a Phase IIb study